Inflammation, cancer and oxidative lipoxygenase activity are intimately linked

Cancers

Volumn 6, Issue 3, 2014, Pages 1500-1521

  Wisastra, Rosalina ^a   Dekker, Frank J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Cancer; Inflammation; Lipoxygenases; Nuclear factor B; Oxidative stress

Indexed keywords

2 [1 METHOXY 1 [3 (2 NAPHTHYLMETHOXY)PHENYL]PROPYL]THIAZOLE; 3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; ARACHIDONIC ACID; DOCEBENONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE; LIPOXIN; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; MONTELUKAST; PHENIDONE; PRANLUKAST; ZAFIRLUKAST; ZILEUTON;

AMINO TERMINAL SEQUENCE; ARTHRITIS; ASTHMA; BIOSYNTHESIS; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; COMPLEX FORMATION; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; ENZYME SUBSTRATE; FATTY ACID SYNTHESIS; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; MALIGNANT NEOPLASTIC DISEASE; METABOLITE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; RHEUMATOID ARTHRITIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

EID: 84904822838     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6031500     Document Type: Review

References (111)

1. Nowsheen, K.; Aziz, T.B.; Kryston, N.F.; Ferguson, N.F.; Georgakilas, A. The interplay between inflammation and oxidative stress and carcinogenesis. Curr. Mol. Med. 2012, 12, 672-680.
2. Haining, J.L.; Axelrod, B. Induction period in the lipoxidase-catalyzed oxidation of linoleic acid and its abolition by substrate peroxide. J. Biol. Chem. 1958, 232, 193-202.
3. Solomon, E.I.; Zhou, J.; Neese, F.; Pavel, E.G. New insights from spectroscopy into the structure/function relationships of lipoxygenases. Chem. Biol. 1997, 4, 795-808.
4. Brash, A.R. Lipoxygenases: Occurrence, Functions, Catalysis, and Acquisition of Substrate. J. Biol. Chem. 1999, 274, 23679-23682.
5. Altschul, S.F.; Gish, W.; Miller, W.; Myers, E.W.; Lipman, D.J. Basic local alignment search tool. J. Mol. Biol. 1990, 215, 403-410.
6. Sigal, E. The molecular biology of mammalian arachidonic acid metabolism. Am. J. Physiol. 1991, 260, L13-L28.
7. Chen, X.; Funk, C.D. The N-terminal "β-Barrel" Domain of 5-Lipoxygenase is Essential for Nuclear Membrane Translocation. J. Biol. Chem. 2001, 276, 811-818.
8. Samuelsson, B. Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science 1983, 220, 568-575.
9. Iversen, L.; Fogh, K.; Bojesen, G.; Kragballe, K. Linoleic acid and dihomogammalinolenic acid inhibit leukotriene B4 formation and stimulate the formation of their 15-lipoxygenase products by human neutrophils in vitro. Evidence of formation of antiinflammatory compounds. Agents Actions 1991, 33, 286-291.
10. Nathaniel, D.J.; Evans, J.F.; Leblanc, Y.; Léveillé, C.; Fitzsimmons, B.J.; Ford-Hutchinson, A.W. Leukotriene A5 is a substrate and an inhibitor of rat and human neutrophil LTA4 hydrolase. Biochem. Biophys. Res. Commun. 1985, 131, 827-835.
11. Brüne, B.; Ullrich, V. 12-hydroperoxyeicosatetraenoic acid inhibits main platelet functions by activation of soluble guanylate cyclase. Mol. Pharmacol. 1991, 39, 671-678.
12. Yeung, J.; Holinstat, M. 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics. Cardiovasc. Hematol. Agents Med. Chem. 2011, 9, 154-164.
13. Ikei, K.N.; Yeung, J.; Apopa, P.L.; Ceja, J.; Vesci, J.; Holman, T.R.; Holinstat, M. Investigations of human platelet-type 12-lipoxygenase: Role of lipoxygenase products in platelet activation. J. Lipid Res. 2012, 53, 2546-2559.
14. Epp, N.; Fürstenberger, G.; Müller, K.; de Juanes, S.; Leitges, M.; Hausser, I.; Thieme, F.; Liebisch, G.; Schmitz, G.; Krieg, P. 12R-lipoxygenase deficiency disrupts epidermal barrier function. J. Cell Biol. 2007, 177, 173-182.
15. Profita, M.; Sala, A.; Riccobono, L.; Pace, E.; Paternò, A.; Zarini, S.; Siena, L.; Mirabella, A.; Bonsignore, G.; Vignola, A.M. 15(S)-HETE modulates LTB4 production and neutrophil chemotaxis in chronic bronchitis. Am. J. Physiol. Cell Physiol. 2000, 279, C1249-C1258.
16. Sordillo, L.M.; Weaver, J.A.; Cao, Y.; Corl, C.; Sylte, M.J.; Mullarky, I.K. Enhanced 15-HPETE production during oxidant stress induces apoptosis of endothelial cells. Prostaglandins Other Lipid Mediat. 2005, 76, 19-34.
17. Hsi, L.C.; Wilson, L.C.; Eling, T.E. Opposing Effects of 15-Lipoxygenase-1 and-2 Metabolites on MAPK Signaling in Prostate: Alteration in peroxisome proliferator-activated receptor γ. J. Biol. Chem. 2002, 277, 40549-40556.
18. Bhatia, B.; Maldonado, C.J.; Tang, S.; Chandra, D.; Klein, R.D.; Chopra, D.; Shappell, S.B.; Yang, P.; Newman, R.A.; Tang, D.G. Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants. J. Biol. Chem. 2003, 278, 25091-25100.
19. Tang, S.; Bhatia, B.; Maldonado, C.J.; Yang, P.; Newman, R.A.; Liu, J.; Chandra, D.; Traag, J.; Klein, R.D.; Fischer, S.M.; et al. Evidence That Arachidonate 15-Lipoxygenase 2 Is a Negative Cell Cycle Regulator in Normal Prostate Epithelial Cells. J. Biol. Chem. 2002, 277, 16189-16201.
20. Rådmark, O. The Molecular Biology and Regulation of 5-Lipoxygenase. Am. J. Respir. Crit. Care Med. 2000, 161, S11-S15.
21. Noguchi, M.; Miyano, M.; Matsumoto, T. Physicochemical characterization of ATP binding to human 5-lipoxygenase. Lipids 1996, 31, 367-371.
22. Peters-Golden, M.; Brock, T.G. 5-Lipoxygenase and FLAP. Prostaglandins Leukot. Essent. Fat. Acids 2003, 69, 99-109.
23. Hunter, J.A.; Finkbeiner, W.E.; Nadel, J.A.; Goetzl, E.J.; Holtzman, M.J. Predominant generation of 15-lipoxygenase metabolites of arachidonic acid by epithelial cells from human trachea. Proc. Natl. Acad. Sci. USA 1985, 82, 4633-4637.
24. Nadel, J.A.; Conrad, D.J.; Ueki, I.F.; Schuster, A.; Sigal, E. Immunocytochemical localization of arachidonate 15-lipoxygenase in erythrocytes, leukocytes, and airway cells. J. Clin. Investig. 1991, 87, 1139-1145.
25. Brash, A.R.; Boeglin, W.E.; Chang, M.S. Discovery of a second 15S-lipoxygenase in humans. Proc. Natl. Acad. Sci. USA 1997, 94, 6148-6152.
26. Brown, C.D.; Kilty, I.; Yeadon, M.; Jenkinson, S. Regulation of 15-lipoxygenase isozymes and mucin secretion by cytokines in cultured normal human bronchial epithelial cells. Inflamm. Res. 2001, 50, 321-326.
27. Chanez, P.; Bonnans, C.; Chavis, C.; Vachier, I. 15-Lipoxygenase. Am. J. Respir. Cell Mol. Biol. 2002, 27, 655-658.
28. Haeggstrom, J.Z.; Wetterholm, A. Enzymes and receptors in the leukotriene cascade. Cell Mol. Life Sci. 2002, 59, 742-753.
29. Okamoto, F.; Saeki, K.; Sumimoto, H.; Yamasaki, S.; Yokomizo, T. Leukotriene B4 Augments and Restores FcγRs-dependent Phagocytosis in Macrophages. J. Biol. Chem. 2010, 285, 41113-41121.
30. Lee, K.S.; Kim, S.R.; Park, H.S.; Park, S.J.; Min, K.H.; Lee, K.Y.; Jin, S.M.; Lee, Y.C. Cysteinyl leukotriene upregulates IL-11 expression in allergic airway disease of mice. J. Allergy Clin. Immunol. 2007, 119, 141-149.
31. Thompson, C.; Cloutier, A.; Bossé, Y.; Poisson, C.; Larivée, P.; McDonald, P.P.; Stankova, J.; Rola-Pleszczynski, M. Signaling by the Cysteinyl-Leukotriene Receptor 2: Involvement in chemokine gene transcription. J. Biol. Chem. 2008, 283, 1974-1984.
32. Kawano, T.; Matsuse, H.; Kondo, Y.; Machida, I.; Saeki, S.; Tomari, S.; Mitsuta, K.; Obase, Y.; Fukushima, C.; Shimoda, T.; et al. Cysteinyl leukotrienes induce nuclear factor κb activation and rantes production in a murine model of asthma. J. Allergy Clin. Immunol. 2003, 112, 369-374.
33. Hoffmann, A.; Natoli, G.; Ghosh, G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene 2006, 25, 6706-6716.
34. Lawrence, T. The Nuclear Factor NF-κB Pathway in Inflammation. Cold Spring Harb. Perspect. Biol. 2009, doi:10.1101/cshperspect. a001651.
35. Zheng, C.; Yin, Q.; Wu, H. Structural studies of NF-kappaB signaling. Cell Res. 2011, 21, 183-195.
36. Karin, M.; Ben-Neriah, Y. Phosphorylation Meets Ubiquitination: The Control of NF-κB Activity. Annu. Rev. Immunol. 2000, 18, 621-663.
37. Holgate, S.T. Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine 2004, 28, 152-157.
38. Williams, R.O.; Paleolog, E.; Feldmann, M. Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases. Curr. Opin. Pharmacol. 2007, 7, 412-417.
39. Chung, K.F. Cytokines as targets in chronic obstructive pulmonary disease. Curr. Drug Targets 2006, 7, 675-681.
40. Perkins, N.D.; Gilmore, T.D. Good cop, bad cop: The different faces of NF-kappaB. Cell Death Differ. 2006, 13, 759-772.
41. Haller, D.; Russo, M.P.; Sartor, R.B.; Jobin, C. IKKβ and Phosphatidylinositol 3-Kinase/Akt Participate in Non-pathogenic Gram-negative Enteric Bacteria-induced RelA Phosphorylation and NF-κB Activation in Both Primary and Intestinal Epithelial Cell Lines. J. Biol. Chem. 2002, 277, 38168-38178.
42. Madrid, L.V.; Mayo, M.W.; Reuther, J.Y.; Baldwin, A.S. Akt Stimulates the Transactivation Potential of the RelA/p65 Subunit of NF-κB through Utilization of the IκB Kinase and Activation of the Mitogen-activated Protein Kinase p38. J. Biol. Chem. 2001, 276, 18934-18940.
43. Perkins, N.D. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 2006, 25, 6717-6730.
44. Bonizzi, G.; Karin, M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004, 25, 280-288.
45. Liu, C.; Xu, D.; Liu, L.; Schain, F.; Brunnström, A.; Björkholm, M.; Claesson, H.E.; Sjöberg, J. 15-Lipoxygenase-1 induces expression and release of chemokines in cultured. human lung epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2009, 297, L196-L203.
46. Ylä-Herttuala, S.; Rosenfeld, M.E.; Parthasarathy, S.; Sigal, E.; Särkioja, T.; Witztum, J.L.; Steinberg, D. Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J. Clin. Investig. 1991, 87, 1146-1152.
47. Li, J.; Rao, J.; Liu, Y.; Cao, Y.; Zhang, Y.; Zhang, Q.; Zhu, D. 15-Lipoxygenase promotes chronic hypoxia-induced pulmonary artery inflammation via positive interaction with nuclear factor-κB. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 971-979.
48. Wu, M.; Lin, T.; Chiu, Y.; Liou, H.; Yang, R.; Fu, W. Involvement of 15-lipoxygenase in the inflammatory arthritis. J. Cell. Biochem. 2012, 113, 2279-2289.
49. Zhao, Y.; Wang, W.; Wang, Q.; Zhang, X.; Ye, L. Lipid metabolism enzyme 5-LOX and its metabolite LTB4 are capable of activating transcription factor NF-κB in hepatoma cells. Biochem. Biophys. Res. Commun. 2012, 418, 647-651.
50. Hui, A.Y.; McCarty, W.J.; Masuda, K.; Firestein, G.S.; Sah, R.L. A systems biology approach to synovial joint lubrication in health, injury, and disease. Wiley Interdiscip. Rev. Syst. Biol. Med. 2012, 4, 15-37.
51. Serhan, C.N. Novel Lipid Mediators and Resolution Mechanisms in Acute Inflammation: To Resolve or Not? Am. J. Pathol. 2010, 177, 1576-1591.
52. Dahlen, S.E.; Bjork, J.; Hedqvist, P.; Arfors, K.E.; Hammarstrom, S.; Lindgren, J.A.; Samuelsson, B. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: In vivo effects with relevance to the acute inflammatory response. Proc. Natl. Acad. Sci. USA 1981, 78, 3887-3891.
53. Chen, M.; Lam, B.K.; Kanaoka, Y.; Nigrovic, P.A.; Audoly, L.P.; Austen, K.F.; Lee, D.M. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J. Exp. Med. 2006, 203, 837-842.
54. Gheorghe, K.R.; Korotkova, M.; Catrina, A.I.; Backman, L.; Klint, E.; Claesson, H.; Radmark, O.; Jakobsson, P. Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids. Arthritis Res. Ther. 2009, 11, R83.
55. Asahara, H.; Asanuma, M.; Ogawa, N.; Nishibayashi, S.; Inoue, H. High DNA-binding activity of transcription factor NF-kappa B in synovial membranes of patients with rheumatoid arthritis. Biochem. Mol. Biol. Int. 1995, 37, 827-832.
56. Jupp, J.; Hillier, K.; Elliott, D.H.; Fine, D.R.; Bateman, A.C.; Johnson, P.A.; Cazaly, A.M.; Penrose, J.F.; Sampson, A.P. Colonic expression of leukotriene-pathway enzymes in inflammatory bowel diseases. Inflamm. Bowel Dis. 2007, 13, 537-546.
57. Stanke-Labesque, F.; Pofelski, J.; Moreau-Gaudry, A.; Bessard, G.; Bonaz, B. Urinary leukotriene E4 excretion: A biomarker of inflammatory bowel disease activity. Inflamm. Bowel Dis. 2008, 14, 769-774.
58. Wang, D.; Dubois, R.N. Eicosanoids and cancer. Nat. Rev. Cancer 2010, 10, 181-193.
59. Pidgeon, G.P.; Tang, K.; Cai, Y.L.; Piasentin, E.; Honn, K.V. Overexpression of Platelet-type 12-Lipoxygenase Promotes Tumor Cell Survival by Enhancing αvβ3 and αvβ5 Integrin Expression. Cancer Res. 2003, 63, 4258-4267.
60. Hennig, R.; Grippo, P.; Ding, X.; Rao, S.M.; Buchler, M.W.; Friess, H.; Talamonti, M.S.; Bell, R.H.; Adrian, T.E. 5-Lipoxygenase, a Marker for Early Pancreatic Intraepithelial Neoplastic Lesions. Cancer Res. 2005, 65, 6011-6016.
61. Steiner, D.R.S.; Gonzalez, N.C.; Wood, J.G. Leukotriene B4 promotes reactive oxidant generation and leukocyte adherence during acute hypoxia. J. Appl. Physiol. 2001, 91, 1160-1167.
62. Kerjaschki, D.; Bago-Horvath, Z.; Rudas, M.; Sexl, V.; Schneckenleithner, C.; Wolbank, S.; Bartel, G.; Krieger, S.; Kalt, R.; Hantusch, B.; et al. Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J. Clin. Investig. 2011, 121, 2000-2012.
63. Wu, Y.; Mao, F.; Zuo, X.; Moussalli, M.J.; Elias, E.; Xu, W.; Shureiqi, I. 15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1α expression in human colon cancer cells. Cancer Med. 2014, 3, 472-484.
64. Suraneni, M.V.; Schneider-Broussard, R.; Moore, J.R.; Davis, T.C.; Maldonado, C.J.; Li, H.; Newman, R.A.; Kusewitt, D.; Hu, J.; Yang, P.; et al. Transgenic expression of 15-lipoxygenase 2 (15-LOX2) in mouse prostate leads to hyperplasia and cell senescence. Oncogene 2010, 29, 4261-4275.
65. Serhan, C.N. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim. Biophys. Acta 1994, 1212, 1-25.
66. Chiang, N.; Arita, M.; Serhan, C.N. Anti-inflammatory circuitry: Lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot. Essent. Fat. Acids 2005, 73, 163-177.
67. Serhan, C.N. Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008, 8, 349-361.
68. Fierro, I.M.; Colgan, S.P.; Bernasconi, G.; Petasis, N.A.; Clish, C.B.; Arita, M.; Serhan, C.N. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin a4 inhibit human neutrophil migration: Comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. J. Immunol. 2003, 170, 2688-2694.
69. Clària, J.; Titos, E.; Jiménez, W.; Ros, J.; Ginès, P.; Arroyo, V.; Rivera, F.; Rodés, J. Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. Gastroenterology 1998, 115, 147-156.
70. Karp, C.L. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 2004, 5, 388-392.
71. Benson, M.; Carlsson, L.; Adner, M.; Jernås, M.; Rudemo, M.; Sjögren, A.; Svensson, P.A.; Uddman, R.; Cardell, L.O. Gene profiling reveals increased expression of uteroglobin and other anti-inflammatory genes in glucocorticoid-treated nasal polyps. J. Allergy Clin. Immunol. 2004, 113, 1137-1143.
72. Chavis, C.; Vachier, I.; Chanez, P.; Bousquet, J.; Godard, P. 5(S),15(S)-dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: Dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors. J. Exp. Med. 1996, 183, 1633-1643.
73. Basselin, M. Anti-inflammatory effects of chronic aspirin on brain arachidonic acid metabolites. Neurochem. Res. 2011, 36, 139-145.
74. Takeda, S.; Jiang, R.; Aramaki, H.; Imoto, M.; Toda, A.; Eyanagi, R.; Amamoto, T.; Yamamoto, I.; Watanabe, K. 9-tetrahydrocannabinol and its major metabolite 9-tetrahydrocannabinol-11-oic acid as 15-lipoxygenase inhibitors. J. Pharm. Sci. 2011, 100, 1206-1211.
75. Whitman, S. Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase. J. Med. Chem. 2002, 45, 2659-2661.
76. Moody, J.S.; Marnett, L.J. Kinetics of Inhibition of Leukocyte 12-Lipoxygenase by the Isoform-Specific Inhibitor 4-(2-Oxapentadeca-4-yne)phenylpropanoic Acid. Biochemistry 2002, 41, 10297-10303.
77. Hong, J.; Bose, M.; Ju, J.; Ryu, J.; Chen, X.; Sang, S.; Lee, M.; Yang, C.S. Modulation of arachidonic acid metabolism by curcumin and related β-diketone derivatives: Effects on cytosolic phospholipase A2, cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004, 25, 1671-1679.
78. Gillard, J.; Ford-Hutchinson, A.W.; Chan, C.; Charleson, S.; Denis, D.; Foster, A.; Fortin, R.; Leger, S.; McFarlane, C.S.; Morton, H. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. 1989, 67, 456-464.
79. Evans, J.F.; Ferguson, A.D.; Mosley, R.T.; Hutchinson, J.H. What's all the FLAP about? 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol. Sci. 2008, 29, 72-78.
80. Friedman, B.S.; Bel, E.H.; Buntinx, A.; Tanaka, W.; Han, Y.R.; Shingo, S.; Spector, R.; Sterk, P. Oral Leukotriene Inhibitor (MK-886) Blocks Allergen-induced Airway Responses. Am. Rev. Respir. Dis. 1993, 147, 839-844.
81. Fruchtmann, R.; Mohrs, K.H.; Hatzelmann, A.; Raddatz, S.; Fugmann, B.; Junge, B.; Horstmann, H.; Muller-Peddinghaus, R. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions 1993, 38, 188-195.
82. Mancini, J.A.; Prasit, P.; Coppolino, M.G.; Charleson, P.; Leger, S.; Evans, J.F.; Gillard, J.W.; Vickers, P.J. 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors. Mol. Pharmacol. 1992, 41, 267-272.
83. Charleson, S.; Evans, J.F.; Leger, S.; Perrier, H.; Prasit, P.; Wang, Z.; Vickers, P.J. Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein. Eur. J. Pharmacol. 1994, 267, 275-280.
84. Werz, O. 5-Lipoxygenase: Cellular Biology and Molecular Pharmacology. Curr. Drug Targets Inflamm. Allergy 2002, 1, 23-44.
85. McMillan, R.M.; Walker, E.R.H. Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol. Sci. 1992, 13, 323-330.
86. Batt, D.G.; Maynard, G.D.; Petraitis, J.J.; Shaw, J.E.; Galbraith, W.; Harris, R.R. 2-Substituted-1-Naphthols as Potent 5-Lipoxygenase Inhibitors with Topical Antiinflammatory Activity. J. Med. Chem. 1990, 33, 360-370.
87. Corey, E.J.; Wright, S.W.; Matsuda, S.P.T. Stereochemistry and mechanism of the biosynthesis of leukotriene A4 from 5(S)-hydroperoxy-6(E),8,11,14(Z)-eicosatetraenoic acid. Evidence for an organoiron intermediate. J. Am. Chem. Soc. 1989, 111, 1452-1455.
88. Doiron, J.; Boudreau, L.H.; Picot, N.; Villebonet, B.; Surette, M.E.; Touaibia, M. Synthesis and 5-lipoxygenase inhibitory activity of new cinnamoyl and caffeoylclusters. Bioorg. Med. Chem. Lett. 2009, 19, 1118-1121.
89. Ford-Hutchinson, A.; Gresser, M.; Young, R.N. 5-Lipoxygenase. Annu. Rev. Biochem. 1994, 63, 383-417.
90. Gillmor, S.A.; Villasenor, A.; Fletterick, R.; Sigal, E.; Browner, M.F. The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. Nat. Struct. Biol. 1997, 4, 1003-1009.
91. Xu, S.; Mueser, T.; Marnett, L.; Funk, M., Jr. Crystal structure of 12-lipoxygenase catalytic-domain-inhibitor complex identifies a substrate-binding channel for catalysis. Structure 2012, 20, 1490-1497.
92. Connolly, P.J.; Wetter, S.K.; Beers, K.N.; Hamel, S.C.; Chen, R.H.K.; Wachter, M.P.; Ansell, J.; Singer, M.M.; Steber, M.; Ritchie, D.M.; et al. N-Hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase. Bioorg. Med. Chem. Lett. 1999, 9, 979-984.
93. Nelson, H.; Kemp, J.; Berger, W.; Corren, J.; Casale, T.; Dube, L.; Walton-Bowen, K.; LaVallee, N.; Stepanians, M. Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: A 3-month randomized controlled study. Ann. Allergy Asthma Immunol. 2007, 99, 178-184.
94. Brooks, C.D.; Stewart, A.O.; Basha, A.; Bhatia, P.; Ratajczyk, J.D.; Martin, J.G.; Craig, R.A.; Kolasa, T.; Bouska, J.B.; Lanni, C. (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. J. Med. Chem. 1995, 38, 4768-4775.
95. Back, M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr. Pharm. Des. 2009, 15, 3116-3132.
96. Gurjar, M.K.; Murugaiah, A.M.S.; Radhakrishna, P.; Ramana, C.V.; Chorghade, M.S. A novel and simple asymmetric synthesis of CMI-977 (LDP-977): A potent anti-asthmatic drug lead. Tetrahedron Asymmetry 2003, 14, 1363-1370.
97. Pergola, C.; Werz, O. 5-Lipoxygenase inhibitors: A review of recent developments and patents. Expert Opin. Ther. Patents 2010, 20, 355-375.
98. Werz, O. Pharmacological intervention with 5-lipoxygenase: New insights and novel compounds. Expert Opin. Ther. Patents 2005, 15, 505-519.
99. Bird, T.G.C.; Bruneau, P.; Crawley, G.C.; Edwards, M.P.; Foster, S.J.; Girodeau, J.M.; Kingston, J.F.; McMillan, R.M. (Methoxyalkyl)thiazoles: A new series of potent, selective, and orally active 5-lipoxygenase inhibitors displaying high enantioselectivity. J. Med. Chem. 1991, 34, 2176-2186.
100. Falgueyret, J.; Hutchinson, J.H.; Riendeau, D. Criteria for the identification of non-redox inhibitors of 5-lipoxygenase. Biochem. Pharmacol. 1993, 45, 978-981.
101. Crawley, G.C.; Dowell, R.I.; Edwards, P.N.; Foster, S.J.; McMillan, R.M.; Walker, E.R.H.; Waterson, D.; Bird, T.G.; Bruneau, P.; Girodeau, J.M. Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors. J. Med. Chem. 1992, 35, 2600-2609.
102. Kusner, E.J.; Buckner, C.K.; Dea, D.M.; DeHaas, C.J.; Marks, R.L.; Krell, R.D. The 5-lipoxygenase inhibitors ZD2138 and ZM230487 are potent and selective inhibitors of several antigen-induced guinea-pig pulmonary responses. Eur. J. Pharmacol. 1994, 257, 285-292.
103. Young, R.N. Inhibitors of 5-lipoxygenase: A therapeutic potential yet to be fully realized? Eur. J. Med. Chem. 1999, 34, 671-685.
104. Wisastra, R.; Ghizzoni, M.; Boltjes, A.; Haisma, H.J.; Dekker, F.J. Anacardic acid derived salicylates are inhibitors or activators of lipoxygenases. Bioorg. Med. Chem. 2012, 20, 5027-5032.
105. Baggelaar, M.P.; Huang, Y.; Feringa, B.L.; Dekker, F.J.; Minnaard, A.J. Catalytic asymmetric total synthesis of (S)-(-)-zearalenone, a novel lipoxygenase inhibitor. Bioorg. Med. Chem. 2013, 21, 5271-5274.
106. Wisastra, R.; Kok, P.A.; Eleftheriadis, N.; Baumgartner, M.P.; Camacho, C.J.; Haisma, H.J.; Dekker, F.J. Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection. Bioorg. Med. Chem. 2013, 21, 7763-7778.
107. Sorkness, C.A. The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma. Pharmacotherapy 1997, 17, 50S-54S.
108. Renzi, P.M. Antileukotriene agents in asthma: The dart that kills the elephant? CMAJ 1999, 160, 217-223.
109. Tintinger, G.R.; Feldman, C.; Theron, A. J; Anderson, R. Montelukast: More than a cysteinyl leukotriene receptor antagonist? ScientificWorldJournal 2010, 10, 2403-2413.
110. Ramires, R.; Caiaffa, M.F.; Tursi, A.; Haeggström, J.Z.; Macchia, L. Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast. Biochem. Biophys. Res. Commun. 2004, 324, 815-821.
111. Tahan, F. Montelukast inhibits tumour necrosis factor-a-mediated interleukin-8 expression through inhibition of nuclear factor-kappaB p65-associated histone acetyltransferase activity. Clin. Exp. Allergy 2008, 38, 805-811.